Backlog of work grows at NIH as staff members are being hounded to quit

Clinical Regulatory News Trials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).

October 17, 2025

Vol.51 No.38

By Edison T. Liu

News Analysis Regulatory News

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter and Jacquelyn Cobb

Guest Editorial

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

When the idea of looking at cancer center funding and the cancer burden of cancer center catchment areas came to us in the summer of 2024, we lived in a different context.

October 17, 2025

Vol.51 No.38

By Todd Burus, Caree McAfee and Pamela C. Hull

Cancer Policy

Federal judge puts temporary block on new round of CDC and HHS layoffs

A federal judge issued a temporary restraining order on Oct. 15, ordering the Trump administration to reverse the wave of layoffs that the administration is using as a pressure tactic intended to force the Democrats to accept cuts to popular health programs and reopen the government.

CDC updates childhood vaccine recommendations

Jim O’Neill, acting director of the Centers for Disease Control and Prevention, announced that he has signed off on a slew of recommendations that change the childhood vaccination schedule.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter

Cancer Policy

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

NIH has published a policy that prohibits U.S. researchers and NIH grant recipients working with human biospecimens to share this data with “countries of concern.” That list includes China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela.

October 10, 2025

Vol.51 No.37

By Sara Willa Ernst

Backlog of work grows at NIH as staff members are being hounded to quit

YOU MAY BE INTERESTED IN

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

Federal judge puts temporary block on new round of CDC and HHS layoffs

CDC updates childhood vaccine recommendations

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Renew today!

Subscriber content

Never miss an issue!

Login

Backlog of work grows at NIH as staff members are being hounded to quit

YOU MAY BE INTERESTED IN

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

Federal judge puts temporary block on new round of CDC and HHS layoffs

CDC updates childhood vaccine recommendations

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Never miss an issue!

Login

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough